ING Group’s Tempest Therapeutics TPST Stock Holding History

ING Group’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-13	Closed	-$57K	–	910
2017 Q2	$57K	Sell	13 -1	-7%	-$4.23K	﹤0.01%	818
2017 Q1	$75K	Buy	+14	New	+$65.2K	﹤0.01%	561

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

ING Group's TPST Position: Q3 2017 in Review

ING Group sold out of Tempest Therapeutics (TPST) in Q3 2017, closing a stake of 13 shares — an estimated $57K sold.

ING Group first reported a position in TPST in Q1 2017 and held it in 2 quarters. The position peaked at $75K in Q1 2017. 47 funds tracked by Wall St. Rank hold TPST as of Q3 2017.

ING Group reported no remaining Tempest Therapeutics position as of Q3 2017 after selling out during the quarter.
ING Group sold 13 Tempest Therapeutics shares in Q3 2017, an estimated $57K.
ING Group first reported a position in Tempest Therapeutics in Q1 2017 and held it in 2 quarters.
ING Group's Tempest Therapeutics position peaked at $75K in Q1 2017.
47 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2017.

Based on ING Group's 13F filing for Q3 2017, filed 8 Nov 2017.